

Treatment of
**Chronic Lymphocytic Leukaemia and
Indolent Non-Hodgkin's Lymphoma :**

Striking a Balance

between **Efficacy** and **Tolerability**

SAVE THE DATE

Date | 15th August 2015, Saturday
Time | 3:15 pm - 9:25 pm
Venue | Level 8, Le Meridien Hotel, Kuala Lumpur

Organized by :



In collaboration with :



Ribomustin®
Bendamustine HCl

3:15pm - 3:35pm | Registration
3:35pm - 3:45pm | Welcome Officiating Speech:
Chairperson : Dr Ng Soo Chin (Consultant Haematologist)
3:45pm - 3:55pm | Official launch:
Dr Mathias J. Rummel, Dr Maximiliano, Dr Ng Soo Chin,
Dr Alan Teh (Consultant Haematologist)
3:55pm - 4:35pm | Presenter: Dr Mathias J. Rummel, M.D., Ph. D.
Chairperson: Dr Ng Soo Chin
Indolent Non-Hodgkin's Lymphoma (iNHL):
• Updates on disease management
• Q & A
4:35pm - 5:05pm | Presenter: Dr Maximiliano Van Kooten
Chairperson: Dr Ng Soo Chin
• Ribomustin data in R-relapsed iNHL
• Q & A
5:05pm - 5:20pm | Tea break
5:20pm - 5:50pm | 2 local NHL case study discussions
Dr Azlan Husin (Consultant Haematologist)
Dr Haris Abdul Rahman (Consultant Haematologist)
5:50pm - 6:00pm | Q & A Adjourn for dinner
6:00pm - 7:30pm | Dinner break
7:30pm - 8:10pm | Presenter: Dr Mathias J. Rummel, M.D., Ph. D.
Chairperson: Dr Ng Soo Chin
Chronic Lymphocytic Leukaemia (CLL):
• Updates on disease management
• Q & A
8:10pm - 8:40pm | Presenter: Dr Maximiliano Van Kooten
Chairperson: Dr Ng Soo Chin
• Ribomustin data in CLL
• Q & A
8:40pm - 9:10pm | 2 local CLL case study discussions
Dr Wan Fariza (Clinical Haematologist)
Dr Henning Loo (Haematology Registrar)
9:10pm - 9:25pm | Q & A Closing Remarks

Johnson & Johnson

SOUTHEAST ASIA
Johnson & Johnson Sdn. Bhd.
3rd Floor, 3.01 Block B, No. 10, Jalan Bersatu 13/4,
46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: +603 7985 6400 Fax: +603 7958 8322

Full prescribing information is available upon request. RIBCO/0715/01



Mathias J. Rummel, M.D., Ph.D.
Head of Haematology

Dr. Mathias J. Rummel, is the head of the Department for Haematology at the Clinic for Haematology and Medical Oncology at the Justus-Liebig University-Hospital, Giessen, Germany. Dr Rummel studied medicine at J.W. Goethe University Hospital in Frankfurt, Germany. There, he also completed his residency, obtained board certification in internal medicine, and was awarded his PhD. Dr. Rummel's research focuses on novel treatment approaches in haematological malignancies, most notably follicular and other indolent lymphomas as well as hairy cell leukaemia and also Idiopathic thrombocytopenic purpura. He is the principal investigator of many clinical trials in leukaemia and lymphoma, and has published several book chapters and papers in peer-reviewed scientific journals.



Maximiliano van Kooten Losio
Medical Oncologist

Maximiliano van Kooten Losio is as medical oncologist from Buenos Aires University. He received his MD from Buenos Aires University-UBA- School of Medicine and Medical Doctor degree with Honors in 1988. He completed Postgraduate Medical training in several disciplines including: Internal Medicine Fellowship. 1989-1991. Jose de San Martin Hospital. Buenos Aires University; Clinical Oncology Fellowship at Buenos Aires University in 1991-1994; Medical Informatics at Salvador University; Statistics for Health Sciences at Buenos Aires University; Clinical Investigation. Max has teaching experiences including Lecturer Assistant, Chemical Biology Chair, School of medicine, Buenos Aires University, 1986-1990; Lecturer Assistant, Physiology Chair, Buenos Aires University, 1985-1988 and Medical Oncology, UCA.

Max has been working as a medical oncologist since 1991 in different institutions including heading the Thoracic Oncology Cancer Service, Alexander Fleming Institute until 2008. His research interests are solid tumours, including thoracic malignancies as well as hematology malignancies and drug development.

In 2008 he moved to Australia and worked as Senior Clinical Research Physician, Eli Lilly Co., Australia & New Zealand. Max has been involved in multiple oncology and supportive clinical studies as primary investigator and publications in peer review international journals.

Max joined Janssen in early 2011 and his current position is Medical Affairs Sr Director Oncology Asia Pacific Region.